COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

Rhea-AI Summary

COMPASS Pathways (Nasdaq: CMPS), a mental health care company, is set to release its financial results for Q4 and the entire year of 2021, along with an update on recent developments, on February 24, 2022. A conference call will follow at 8:00 AM ET, accessible via phone and webcast. COMPASS is pioneering a new model of psilocybin therapy, recently achieving significant results in a large-scale clinical trial for treatment-resistant depression.

COMP360, its breakthrough therapy, is currently in further clinical trials for PTSD.

Positive

• Achieved statistically significant improvement in depressive symptoms in phase IIb trial.
• COMP360 designated as Breakthrough Therapy by the FDA.
• Conducted the largest randomized controlled psilocybin therapy trial to date.

Negative

• None.

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.

The management team will host a conference call at 8:00am ET (1:00pm UK) on 24 February. The call can be accessed by dialing (833) 665-0659 from the United States, (914) 987-7313 internationally, and 0800 028 8438 from the UK, followed by the conference ID: 2825279.

The call will also be webcast on the Investors section of the COMPASS Pathways website. The webcast will be archived for 30 days.

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com

Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.        

Enquiries

Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324

FAQ

When will COMPASS Pathways release its Q4 2021 financial results?

COMPASS Pathways will release its Q4 2021 financial results on February 24, 2022.

What is COMP360 and its significance for COMPASS Pathways?

COMP360 is a proprietary formulation of synthetic psilocybin, designated as a Breakthrough Therapy for treatment-resistant depression by the FDA.

What were the results of the phase IIb clinical trial for COMP360?

The phase IIb clinical trial showed a statistically significant improvement in depressive symptom severity after three weeks.

How can investors access the COMPASS Pathways conference call?

Investors can access the conference call by dialing specific numbers provided in the press release or through the webcast on the company's investor relations website.

What additional trials is COMPASS Pathways conducting?

COMPASS Pathways is also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).